Mumbai: Generic pharmaceutical company BDR pharma announced the launch of Cabozantinib which can treat metastatic medullary thyroid cancer, advanced renal cell carcinoma and hepatocellular carcinoma.

Cabozantinib is prescribed for treating patients with progressive, metastatic medullary thyroid cancer (MTC) and as a second-line treatment for renal cell carcinoma apart from treating hepatocellular carcinoma. The drug works by blocking (inhibiting) the signals inside cancer cells that make them grow and divide. In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, CABOZANIB has shown better PFS (Progression-Free Survival).

Elucidating on the efforts that went into developing the drug, Raheel Shah, Director of Business Development, BDR Pharmaceuticals, said: “World-class treatment at a reasonable rate was the main reason for launching the drug in India. Though we have been outstretched in all departments to deliver on COVID treatment on an emergency basis, we have not allowed this to hamper our efforts on other equally important priority segments, including oncology. The result is the advent of development of this new generic cancer molecule called Cabozantinib(Cabozanib). “

As DGCI approved BDR Pharma’s Cabozantinib to be put into medicinal use, the company claimed that it will soon make it available in the market for treatment.

Source link

By Sam

Leave a Reply

Your email address will not be published. Required fields are marked *